SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Oertel W H)
 

Sökning: WFRF:(Oertel W H) > Effects of teripara...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003291naa a2200385 4500
001oai:DiVA.org:uu-167184
003SwePub
008120123s2012 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1671842 URI
0247 a https://doi.org/10.1530/EJE-11-07402 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Jakob, F.4 aut
2451 0a Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates :b 36-month results from the European Forsteo Observational Study
264 1c 2012
338 a print2 rdacarrier
520 a Objectives: To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months. Design: Prospective, multinational, and observational study. Methods: Data on prior bisphosphonate use, clinical fractures, back pain visual analog scale (VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed using a repeated measures model. Results: Of the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior bisphosphonate use (median duration: 36 months). Of them, 169 (14.6%) sustained >= 1 fracture during 36-month follow-up. Adjusted odds of fracture were significantly decreased at each 6-month interval compared with the first 6 months of teriparatide treatment: 37% decrease in the 12 to ! 18 months period during teriparatide treatment (P=0.03) and a 76% decrease in the 12- to 18-month period after teriparatide was discontinued (P<0.001). Significant reductions in back pain and improvement in HRQoL were observed. Conclusions: Postmenopausal women with severe osteoporosis previously treated with bisphosphonates had a significant reduction in the incidence of fractures compared with the first 6 months of therapy, a reduction in back pain and an improvement in HRQoL during up to 18 months of teriparatide treatment. These outcomes were still evident for at least 18 months after teriparatide was discontinued. The results should be interpreted in the context of an uncontrolled, observational study in a routine clinical setting.
7001 a Oertel, H.4 aut
7001 a Langdahl, B.4 aut
7001 a Ljunggren, Östenu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)osteljun
7001 a Barrett, A.4 aut
7001 a Karras, D.4 aut
7001 a Walsh, J. B.4 aut
7001 a Fahrleitner-Pammer, A.4 aut
7001 a Rajzbaum, G.4 aut
7001 a Barker, C.4 aut
7001 a Lems, W. F.4 aut
7001 a Marin, F.4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t European Journal of Endocrinologyg 166:1, s. 87-97q 166:1<87-97x 0804-4643x 1479-683X
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-167184
8564 8u https://doi.org/10.1530/EJE-11-0740

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy